-

02:26:41 AM

EIGR Stock News

EIGR - Eiger BioPharmaceuticals Inc

09/22/22 8:00 AM

Nasdaq : EIGR

conferences

Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : EIGR

covid-19

Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today provided an update on the status of its

RHEA-AI

neutral

09/01/22 8:00 AM

Nasdaq : EIGR

conferences

Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management

RHEA-AI

neutral

08/04/22 4:05 PM

Nasdaq : EIGR

earnings

Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated Approval of Zokinvy in Europe; Partnership with AnGes in Japan Strong

RHEA-AI

very positive

07/28/22 8:00 AM

Nasdaq : EIGR

conferencesearnings

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious

RHEA-AI

neutral

07/20/22 8:00 AM

Nasdaq : EIGR

Eiger Receives European Approval for Zokinvy(R) (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

First and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies 1 Extended life by an average of 4.3 years in children and young adults with HGPS 2 Now approved for use in 30 European countries, following approval in the U.S

RHEA-AI

very positive

07/18/22 8:00 AM

Nasdaq : EIGR

management

Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors

Eiger BioPharmaceuticals, Inc. ( Nasdaq : EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus ( HDV) and other serious diseases, today announced the

RHEA-AI

very positive

06/27/22 4:05 PM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress(TM) 2022

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced data presented

RHEA-AI

neutral

06/13/22 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries

- Data presented in oral presentation at ENDO 2022 on June 11- Avexitide significantly reduced the number of hypoglycemia events and the amount of time spent in hypoglycemia- Study included patients who had undergone gastric bypass, vertical sleeve, total gastrectomy, or Nissen fundoplication

RHEA-AI

neutral

06/08/22 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress(TM) 2022

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure

RHEA-AI

neutral

1 2 3 4 5 6 7 Next